Trial Profile
A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Aluminium phosphate
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors BiondVax Pharmaceuticals; Scinai Immunotherapeutics
- 12 Jan 2017 Results presented at The Vaccine journal, as reported by a BiondVax Pharmaceuticals media release.
- 12 Jan 2017 Results published in a BiondVax Pharmaceuticals media release.
- 05 Jan 2017 Results published in the Vaccine.